Compare GNK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | INBX |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 967.7M | 999.7M |
| IPO Year | 2005 | 2024 |
| Metric | GNK | INBX |
|---|---|---|
| Price | $25.28 | $137.95 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $19.00 | ★ $150.00 |
| AVG Volume (30 Days) | 252.0K | ★ 448.7K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $342,054,000.00 | $1,300,000.00 |
| Revenue This Year | $21.15 | N/A |
| Revenue Next Year | $1.41 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $12.66 | $10.90 |
| 52 Week High | $25.66 | $155.29 |
| Indicator | GNK | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 62.93 | 80.46 |
| Support Level | $22.40 | $69.30 |
| Resistance Level | N/A | $155.29 |
| Average True Range (ATR) | 0.78 | 12.12 |
| MACD | 0.10 | 2.25 |
| Stochastic Oscillator | 94.16 | 80.24 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.